The Foundation for Prader-Willi Research

Palobiofarma is a Spanish Biotech company located in Barcelona’s Science Park. Our mission is to discover and develop new drugs based on the modulation of the adenosine receptors. Our vision is to be the first european adenosine drug discovery company

Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics was founded by Tien Lee in 2017.

Lipidio Pharmaceuticals is a healthcare company that focuses on advancing a molecule to treat diseases associated with excess body fat. It includes non-alcoholic steatohepatitis, Prader-Willi syndrome, and antipsychotic drug-induced weight gain. The company was founded in 2018 and headquartered in San Diego, California.

Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions.